What is New in Pharmacologic Therapy for Cardiac Resuscitation?

Antiarrhythmic therapy can be a critical component of cardiac resuscitation. Therapies in this area have seen little advance in the last decade. Bretylium, a very old drug, has been reintroduced for ventricular tachycardia/ventricular fibrillation (VT/VF) therapy. There are still important questions...

Descripción completa

Detalles Bibliográficos
Autores principales: Somberg, John, Molnar, Janos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239592/
https://www.ncbi.nlm.nih.gov/pubmed/32494323
http://dx.doi.org/10.14740/cr1058
_version_ 1783536720608755712
author Somberg, John
Molnar, Janos
author_facet Somberg, John
Molnar, Janos
author_sort Somberg, John
collection PubMed
description Antiarrhythmic therapy can be a critical component of cardiac resuscitation. Therapies in this area have seen little advance in the last decade. Bretylium, a very old drug, has been reintroduced for ventricular tachycardia/ventricular fibrillation (VT/VF) therapy. There are still important questions to be addressed with bretylium: when to administer (first- or second-line) and at which dose. These questions and the development of newer agents will be areas of future research.
format Online
Article
Text
id pubmed-7239592
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-72395922020-06-02 What is New in Pharmacologic Therapy for Cardiac Resuscitation? Somberg, John Molnar, Janos Cardiol Res Review Antiarrhythmic therapy can be a critical component of cardiac resuscitation. Therapies in this area have seen little advance in the last decade. Bretylium, a very old drug, has been reintroduced for ventricular tachycardia/ventricular fibrillation (VT/VF) therapy. There are still important questions to be addressed with bretylium: when to administer (first- or second-line) and at which dose. These questions and the development of newer agents will be areas of future research. Elmer Press 2020-06 2020-05-03 /pmc/articles/PMC7239592/ /pubmed/32494323 http://dx.doi.org/10.14740/cr1058 Text en Copyright 2020, Somberg et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Somberg, John
Molnar, Janos
What is New in Pharmacologic Therapy for Cardiac Resuscitation?
title What is New in Pharmacologic Therapy for Cardiac Resuscitation?
title_full What is New in Pharmacologic Therapy for Cardiac Resuscitation?
title_fullStr What is New in Pharmacologic Therapy for Cardiac Resuscitation?
title_full_unstemmed What is New in Pharmacologic Therapy for Cardiac Resuscitation?
title_short What is New in Pharmacologic Therapy for Cardiac Resuscitation?
title_sort what is new in pharmacologic therapy for cardiac resuscitation?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239592/
https://www.ncbi.nlm.nih.gov/pubmed/32494323
http://dx.doi.org/10.14740/cr1058
work_keys_str_mv AT sombergjohn whatisnewinpharmacologictherapyforcardiacresuscitation
AT molnarjanos whatisnewinpharmacologictherapyforcardiacresuscitation

Ejemplares similares